Insider filing · TSHA
Sukumar Nagendran
President and Head of R&D
profile →
Taysha Gene Therapies, Inc.
TSHA · Healthcare · 11 filings in 24 months
ticker →
Sukumar Nagendran sold $942K of Taysha Gene Therapies (TSHA)
Executed Jan 12, disclosed Jan 14, 2 days later.
Value, as filed
$942K
200,000 sh × $4.71
Executed
Jan 12
the trade date, as filed
Disclosed
Jan 14
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
SNSukumar Nagendran (President and Head of R&D) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Taysha Gene Therapies, Inc. (TSHA). The largest single filing was $1.7M of TSHA (370,172 sh across 2 lots, as filed), executed Nov 28 2025.
The name
TSHAHealthcare · Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Sukumar Nagendran in TSHA
TSHASALE
Taysha Gene Therapies, Inc.
$1.2M200,000 sh × $6.24
Exec Jul 10
Filed Jul 10 · 6:54 PM ET TSHASALE Taysha Gene Therapies, Inc. $892K
200,000 sh × $4.46
Exec Apr 10
Filed Apr 13 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $547K
116,050 sh across 2 lots
Exec Jan 23
Filed Jan 27 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $1.7M
370,172 sh across 2 lots
Exec Nov 28 2025
Filed Dec 1 2025 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $646K
200,000 sh × $3.23
Exec Sep 10 2025
Filed Sep 12 2025 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $163K
57,054 sh × $2.85
Exec Aug 21 2025
Filed Aug 22 2025 · 5:30 PM ET